Education
About Us
Working with TipRanks
Follow Us
SciSparc Ltd. (SPRC)
NASDAQ:SPRC
SPRC Stock Chart & Stats
$1.46
-$0.23(-22.16%)
At close: 4:00 PM EST
$1.46
-$0.23(-22.16%)
Day’s Range― - ―
52-Week Range$1.55 - $37.59
Previous CloseN/A
Volume2.49M
Average Volume (3M)207.26K
Market Cap
$4.78M
Enterprise Value$4.29M
Total Cash (Recent Filing)$1.57M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.87
Shares Outstanding3,276,378
10 Day Avg. Volume21,771
30 Day Avg. Volume207,260
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)5.40
Price to Sales (P/S)33.72
P/FCF Ratio-8.63
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit21.11
Enterprise Value/Ebitda-0.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-671.58
Revenue Forecast (FY)N/A
SciSparc Ltd. News
SPRC FAQ
What was SciSparc Ltd.’s price range in the past 12 months?
SciSparc Ltd. lowest stock price was $1.55 and its highest was $37.59 in the past 12 months.
What is SciSparc Ltd.’s market cap?
SciSparc Ltd.’s market cap is $4.78M.
When is SciSparc Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SciSparc Ltd.’s earnings last quarter?
Currently, no data Available
Is SciSparc Ltd. overvalued?
According to Wall Street analysts SciSparc Ltd.’s price is currently Overvalued.
Does SciSparc Ltd. pay dividends?
SciSparc Ltd. does not currently pay dividends.
What is SciSparc Ltd.’s EPS estimate?
SciSparc Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciSparc Ltd. have?
SciSparc Ltd. has 3,276,378 shares outstanding.
What happened to SciSparc Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SciSparc Ltd.?
Currently, no hedge funds are holding shares in SPRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciSparc Ltd.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Technical Analysis
Alaunos Therapeutics
―
Entero Therapeutics
―
PharmaCyte Biotech
―
Ensysce Biosciences
―
Polyrizon Ltd.
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---